Innovative Cell Therapies TeraImmune specializes in developing regulatory T cell therapies for autoimmune diseases like multiple sclerosis, presenting opportunities for collaborations or technology licensing with biotech companies seeking to expand their immunotherapy portfolios.

Recent Clinical Progress The launch of TI-168 and ongoing development of cGMP manufacturing protocols position TeraImmune as a promising partner for clinical-stage biotech firms seeking to accelerate their cell therapy development and manufacturing capabilities.

Strategic Partnerships Recent collaborations with companies like Baudax Bio and ongoing ties with the NIAID highlight TeraImmune’s potential as a strategic partner for organizations seeking innovative Treg-based solutions or expanding their immunology pipelines.

Grant-backed Validation Securing NIH grants such as SBIR and PACT underscores the scientific credibility of TeraImmune’s platform, making them an attractive partner for funding agencies and investors interested in cutting-edge immunotherapy innovations.

Growth & Expansion With a focused team and recent product launches, TeraImmune offers growth opportunities for suppliers and service providers specializing in biotech manufacturing, regulatory consulting, and clinical trial support tailored to cell therapy development.